PhaseBio Pharmaceuticals Stock Forecast, Price & News

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

Is PhaseBio Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals or view top-rated stocks.

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHAS shares have decreased by 28.4% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for PhaseBio Pharmaceuticals.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analysts' expectations of $2.67 million.
View PhaseBio Pharmaceuticals' earnings history.

What price target have analysts set for PHAS?

3 brokerages have issued 1-year price objectives for PhaseBio Pharmaceuticals' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 569.6% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:

• Jonathan P. Mow, Chief Executive Officer & Director
• John P. Sharp, Chief Financial Officer
• John S. Lee, Chief Medical Officer
• Kristopher L. Hanson, Secretary, Vice President & Head-Legal
• Susan E. Arnold, Vice President-Preclinical & CMC

Who are some of PhaseBio Pharmaceuticals' key competitors?

Some companies that are related to PhaseBio Pharmaceuticals include G1 Therapeutics (GTHX), Spero Therapeutics (SPRO), Oramed Pharmaceuticals (ORMP), Applied Molecular Transport (AMTI), Vera Therapeutics (VERA), Allakos (ALLK), Rigel Pharmaceuticals (RIGL), ESSA Pharma (EPIX), Marinus Pharmaceuticals (MRNS), Verona Pharma (VRNA), Nkarta (NKTX), Generation Bio (GBIO), Xilio Therapeutics (XLO), Geron (GERN) and Akebia Therapeutics (AKBA).
View all of PHAS's competitors.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Spire Wealth Management (0.53%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, Edmund Harrigan and Glen Burkhardt.
View institutional ownership trends for PhaseBio Pharmaceuticals.

Which major investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was acquired by a variety of institutional investors in the last quarter, including Spire Wealth Management. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, and Edmund Harrigan.
View insider buying and selling activity for PhaseBio Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $2.24.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals has a market capitalization of $107.72 million and generates $320 thousand in revenue each year. The company earns $-98.57 million in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does PhaseBio Pharmaceuticals have?

PhaseBio Pharmaceuticals employs 50 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

Where are PhaseBio Pharmaceuticals' headquarters?

PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Parkway Suite 30, Malvern PA, 19355.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at (610) 981-6500 or via email at [email protected].